NRX Pharmaceuticals, Inc. (NRXP)

In March 2026, the company reported its full-year 2025 results, highlighting reduced operating expenses, $7.8 million cash on hand, and anticipated FDA approval of its preservative-free ketamine therapy (NRX-100) as early as Q3 2026, leading to a stock increase of 20.34%. In April 2026, NRx Pharmaceuticals welcomed a Presidential Initiative aimed at accelerating the approval of psychedelic medications, resulting in a gain of 25.49% on the day. Also in April 2026, the company announced positive FDA Office of Generic Drugs feedback on its preservative-free ketamine program and the appointment of Glenn Tyson as its first Chief Commercial Officer. In May 2026, NRx Pharmaceuticals announced the initiation of commercial manufacturing for its preservative-free ketamine product (NRX-100) and the FDA cleared NRX Pharmaceuticals to proceed with a clinical trial of NRX-101 in combination with robotic-enabled Transcranial Magnetic Stimulation. In April 2026, short interest in NRXP rose by 29.4% to 3,248,961 shares, representing about 10.5% of the float.

The provided information does not contain specific details regarding the demand seasonality for NRX Pharmaceuticals, Inc.'s products and services. Demand for its products would likely be driven by medical need and regulatory approvals rather than traditional seasonal patterns. The services offered through HOPE Therapeutics clinics may experience consistent demand throughout the year, though specific seasonality data is not available.

NRX Pharmaceuticals, Inc. (NRXP) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for central nervous system disorders, including suicidal depression, bipolar depression, chronic pain, post-traumatic stress disorder (PTSD), and schizophrenia. The company operates within the Healthcare sector and the Biotechnology industry. NRX-100 (Preservative-Free Intravenous Ketamine / KETAFREE™) is being developed for the treatment of suicidal depression and has received Fast Track Designation from the FDA. NRX Pharmaceuticals has initiated the filing of a New Drug Application (NDA) for NRX-100 and is also pursuing an Abbreviated New Drug Application (ANDA) for a generic preservative-free formulation of ketamine. NRX-101 (Oral D-cycloserine/lurasidone) is an oral fixed-dose combination therapy targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression and has received Breakthrough Therapy Designation from the FDA. The company is also exploring its use for chronic pain, PTSD, and complicated urinary tract infections (cUTI), and for augmenting Transcranial Magnetic Stimulation (TMS) for depression and suicidality. HOPE Therapeutics, Inc. is a wholly-owned subsidiary operating as a healthcare delivery or interventional psychiatry network, building a network of clinics that offer neuroplastic therapies.

NRX Pharmaceuticals, Inc. is headquartered in Wilmington, Delaware, United States. Its subsidiary, HOPE Therapeutics, Inc., is establishing a national network of interventional psychiatry clinics, with revenue-generating facilities currently operating in Florida and plans for expansion through acquisitions in Florida, the Mid-Atlantic, and the Midwest.

In the past year, NRX Pharmaceuticals' brand reputation appears to have been positively influenced by progress in clinical trials and regulatory submissions for NRX-100 and NRX-101. Receiving Fast Track Designation for NRX-100 and Breakthrough Therapy Designation for NRX-101 highlights the potential significance and urgency of their therapies. Positive feedback from the FDA on its preservative-free ketamine program and the initiation of commercial manufacturing for NRX-100 indicate advancement towards market availability. The company's alignment with a presidential initiative to accelerate the approval of psychedelic medications for mental health conditions further bolsters its image. The development of a national network of interventional psychiatry clinics through HOPE Therapeutics demonstrates a commitment to patient care.

NRX Pharmaceuticals, Inc. has a diversified ownership structure including institutional, retail, and individual investors. As of May 2026, 33 institutional owners and shareholders hold a total of 5,356,156 shares, including Anson Funds Management LP, Vanguard Group Inc., and AdvisorShares Investments LLC. Daniel C. Javitt and Chaim Hurvitz are significant individual shareholders. Approximately 9.47% to 15.31% of the company's stock is owned by institutional investors, 8.77% to 11.41% by insiders, and 75.91% to 79.11% by public companies and individual investors.